Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Common Equity (2016 - 2025)

Historic Common Equity for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to $713.0 million.

  • Viking Therapeutics' Common Equity fell 2176.95% to $713.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $713.0 million, marking a year-over-year decrease of 2176.95%. This contributed to the annual value of $880.3 million for FY2024, which is 15264.93% up from last year.
  • Viking Therapeutics' Common Equity amounted to $713.0 million in Q3 2025, which was down 2176.95% from $795.5 million recorded in Q2 2025.
  • Over the past 5 years, Viking Therapeutics' Common Equity peaked at $933.9 million during Q1 2024, and registered a low of $134.1 million during Q1 2023.
  • For the 5-year period, Viking Therapeutics' Common Equity averaged around $461.1 million, with its median value being $348.4 million (2023).
  • As far as peak fluctuations go, Viking Therapeutics' Common Equity crashed by 2901.45% in 2022, and later soared by 59659.64% in 2024.
  • Over the past 5 years, Viking Therapeutics' Common Equity (Quarter) stood at $201.9 million in 2021, then dropped by 28.02% to $145.3 million in 2022, then surged by 139.76% to $348.4 million in 2023, then soared by 152.65% to $880.3 million in 2024, then fell by 19.0% to $713.0 million in 2025.
  • Its Common Equity stands at $713.0 million for Q3 2025, versus $795.5 million for Q2 2025 and $846.9 million for Q1 2025.